Association of Polymorphic Markers of the TP53, MDM2, and CDKN1A Genes with the Risk of Ovarian Cancer

被引：0
|
作者：
P. K. Brenner
M. A. Kapralova
D. S. Khodyrev
S. V. Khokhlova
G. N. Khabas
A. V. Asaturova
Yu. V. Nosova
L. N. Kayumova
T. M. Zavarykina
机构：
[1] Emanuel Institute of Biochemical Physics,
[2] Russian Academy of Sciences,undefined
[3] Federal Scientific and Clinical Center of Specialized Types of Medical Care and Medical Technologies of the Federal Medical and Biological Agency of the Russian Federation,undefined
[4] Kulakov National Medical Research Center of Obstetrics,undefined
[5] Gynecology and Perinatology,undefined
[6] Sechenov First Moscow State Medical University (Sechenov University),undefined
来源：
Russian Journal of Genetics | 2022年 / 58卷
关键词：
ovarian cancer; polymorphic marker; cell cycle control; apoptosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1154 / 1158
页数：4
相关论文
共 50 条
  • [31] Mass Spectrometry based Methylation Analysis of MDM2, CDKN2A, RB1, TP53 and TP73 and Associations to MDM2 Overexpression in Malignant Pleural mesothelioma
    Mairinger, F.
    Meier, S.
    Wessolly, M.
    Koehler, C.
    Wagner, F.
    Mairinger, E.
    Schmeller, J.
    Borchert, S.
    Wohlschlaeger, J.
    Ploenes, T.
    Hager, T.
    Rozynek, P.
    Kollmeier, J.
    Christoph, D.
    Schmid, K. W.
    Mairinger, T.
    Johnen, G.
    Walter, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 115 - 115
  • [32] MDM2 OVEREXPRESSION IS RARE IN OVARIAN-CARCINOMA IRRESPECTIVE OF TP53 MUTATION STATUS
    FOULKES, WD
    STAMP, GWH
    AFZAL, S
    LALANI, N
    MCFARLANE, CP
    TROWSDALE, J
    CAMPBELL, IG
    BRITISH JOURNAL OF CANCER, 1995, 72 (04) : 883 - 888
  • [33] Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer
    Zhang, XM
    Miao, XP
    Guo, YL
    Tan, W
    Zhou, YF
    Sun, T
    Wang, YG
    Lin, DX
    HUMAN MUTATION, 2006, 27 (01) : 110 - 117
  • [34] ALTERED PATTERNS OF MDM2 AND TP53 EXPRESSION IN HUMAN BLADDER-CANCER
    LIANES, P
    ORLOW, I
    ZHANG, ZF
    OLIVA, MR
    SARKIS, AS
    REUTER, VE
    CORDONCARDO, C
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (17) : 1325 - 1330
  • [35] Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer
    Ashton, Katie A.
    Proietto, Anthony
    Otton, Geoffrey
    Symonds, Ian
    McEvoy, Mark
    Attia, John
    Gilbert, Michael
    Hamann, Ute
    Scott, Rodney J.
    GYNECOLOGIC ONCOLOGY, 2009, 113 (01) : 109 - 114
  • [36] Molecular alterations of the RB1, TP53, and MDM2 genes in primary and xenografted human osteosarcomas
    Pellin, A
    Boix-Ferrero, J
    Carpio, D
    Lopez-Terrada, D
    Carda, C
    Navarro, S
    Peydro-Olaya, A
    Triche, TJ
    Llombart-Bosch, A
    DIAGNOSTIC MOLECULAR PATHOLOGY, 1997, 6 (06) : 333 - 341
  • [37] Knockdown of PRKD2 Enhances Chemotherapy Sensitivity in Cervical Cancer via the TP53/CDKN1A Pathway
    Feng, Ruijing
    Wang, Xin
    Chen, Hongwei
    Cao, Chen
    Liu, Ting
    Zhao, Tong
    Chen, Huang
    Tian, Rui
    Ni, Yangyang
    Tian, Xun
    Hu, Zheng
    Ma, Ji
    Gong, Danni
    CURRENT CANCER DRUG TARGETS, 2023, 23 (02) : 159 - 170
  • [38] Impact of MDM2, TP53 and P14ARF Polymorphisms on Endometrial Cancer Risk and Onset
    Wujcicka, Wioletta
    Zajac, Agnieszka
    Stachowiak, Grzegorz
    IN VIVO, 2019, 33 (03): : 917 - 924
  • [39] Status Analysis of the Genes MYCN, MDM2 and TP53 and Protein Expression of MDM2, P53 and PRB in Patients with Retinoblastoma Underwent Enucleation
    Carvalho Filho, N.
    Cunha, I. Werneck
    Ribeiro, K. Braga
    Antoneli, C. B. Gianotti
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S144 - S144
  • [40] Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma
    Ohnstad, Hege O.
    Castro, Russell
    Sun, Jinchang
    Heintz, Karen-Marie
    Vassilev, Lyubomir T.
    Bjerkehagen, Bodil
    Kresse, Stine H.
    Meza-Zepeda, Leonardo A.
    Myklebost, Ola
    CANCER, 2013, 119 (05) : 1013 - 1022
12345